<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768170</url>
  </required_header>
  <id_info>
    <org_study_id>0633-028</org_study_id>
    <secondary_id>MK0633-028</secondary_id>
    <secondary_id>2008_552</secondary_id>
    <nct_id>NCT00768170</nct_id>
  </id_info>
  <brief_title>MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)</brief_title>
  <official_title>A Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK0633 in Japanese Asthmatic Children Aged 12 to Less Than 16 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability and pharmacokinetics (PK) of MK0633 in
      adolescent mild-to-moderate Japanese asthma patients to permit further clinical investigation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of MK0633 in adolescent asthma patients based on any clinical or laboratory adverse experiences</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0633</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0633</intervention_name>
    <description>MK0633 (50 mg) Oral, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient Is Judged To Be In Good Health, Other Than Having Mild To Moderate Asthma,
             Based On Medical History, Physical Examination, Vital Signs, And Laboratory Safety
             Tests

          -  Patient Has No Clinically Significant Abnormality On Electrocardiogram (Ecg) Performed
             At The Prestudy (Screening) Visit And/Or Prior To Administration Of The Initial Dose
             Of Study Drug

          -  Patient Has At Least 1 Year Of Mild-To-Moderate Asthma

          -  Patient Has Been A Nonsmoker For At Least 6 Months

          -  Patients Of Childbearing Potential Must Agree To Use A Medically Acceptable Method Of
             Contraception During The Study

          -  Patients Must Be Able To Swallow Tablets

        Exclusion Criteria:

          -  Patient Has A History Of Clinically Significant Endocrine, Gastrointestinal,
             Cardiovascular, Hematological, Hepatic, Immunological, Renal, Respiratory, Other Than
             Asthma, Or Genitourinary Abnormalities Or Diseases

          -  Patient Has Required A Visit To A Hospital Or Emergency Room Due To An Asthma
             Exacerbation Within 3 Months Of The Prestudy Visit

          -  Patient Has Unresolved Signs And Symptoms Of An Upper Respiratory Tract Infection
             (Uri) Or Has Had Had An Upper Respiratory Tract Infection Within 3 Weeks Prior To The
             Prestudy Visit

          -  Patient Has A History Of Stroke, Chronic Seizures, Or Major Neurological Disorder

          -  Patient Has A History Of Neoplastic Disease

          -  Use Of Theophylline, Anti-Allergic Compounds (Except For Nasal Drop And Eye-Drop
             Omalizumab, Zileuton, Oral Corticosteroid, And Oral Beta Agonists (Including Patch)
             Are Excluded ~ 2 Weeks Prior To Administration Of Study Drug And Throughout The Study
             7)Patient Consumes Alcoholic Beverages
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

